Europe Biologics Market
The Europe biologics market was valued at US$ 1,15,057.6 million in 2023 and is expected to reach US$ 4,15,468.4 million by 2031; it is estimated to register a CAGR of 17.4% from 2023 to 2031. Preference for Outsourcing Manufacturing Operations Drives Europe Biologics Market
Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.Europe Biologics Market Overview
The biologics market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe holds the second-largest market share, which can be attributed to the increasing cancer burden and technological advancements in cancer diagnostics to aid in early detection. The growing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is also contributing to the biologics market progress in Europe. Germany invests significantly in healthcare research and infrastructure among all countries in the European Union (EU). According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015, which was one of the highest among the relative countries in the region. According to OECD Health Statistics 2015, health spending in Germany is growing faster than the actual OECD-predicted average; this can be associated with the higher capital investments made to support the development, research, and manufacturing of pharmaceuticals. Thus, the robust financial backing to the healthcare sector bolsters the biologics market in Germany.
Europe Biologics Market Revenue and Forecast to 2031 (US$ Million)
Strategic insights for the Europe Biologics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Biologics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Europe Biologics Strategic Insights
Get more information on this report Europe Biologics Report Scope
Report Attribute
Details
Market size in 2023
US$ 1,15,057.6 Million
Market Size by 2031
US$ 4,15,468.4 Million
Global CAGR (2023 - 2031)
17.4%
Historical Data
2025-2031
Forecast period
2021-2023
Segments Covered
By Product
By Application
By Source
By Manufacturing
Regions and Countries Covered
Europe
Market leaders and key company profiles
Get more information on this report Europe Biologics Regional Insights
Get more information on this report
Europe Biologics Market Segmentation
The Europe biologics market is categorized into product, application, source, manufacturing, and country.
Based on product, the Europe biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.
In terms of application, the Europe biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.
By source, the Europe biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.
Based on manufacturing, the Europe biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.
In terms of country, the Europe biologics market is segmented into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe biologics market share in 2023.
AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Europe biologics market.
The Europe Biologics Market is valued at US$ 1,15,057.6 Million in 2023, it is projected to reach US$ 4,15,468.4 Million by 2031.
As per our report Europe Biologics Market, the market size is valued at US$ 1,15,057.6 Million in 2023, projecting it to reach US$ 4,15,468.4 Million by 2031. This translates to a CAGR of approximately 17.4% during the forecast period.
The Europe Biologics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Biologics Market report:
The Europe Biologics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Biologics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Biologics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Biologics Market
